培美曲塞联合奥沙利铂治疗肺腺癌的临床观察  

Clinical experience of pemetrexed combined with oxaliplatin treating patients with lung adenocarcinoma

作　　者：李苏霞[1] 费正华[1] 李陈萍[1] 曾谦[1] 刘洁凡[1] 陈素秀[1] 

机构地区：[1]温州医学院附属第一医院全科医学科,温州浙江325000

出　　处：《中华肿瘤防治杂志》2010年第20期1674-1675,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：为了评价国产培美曲塞联合国产奥沙利铂一线治疗中晚期非小细胞肺腺癌的疗效和毒副反应,对40例经病理确诊为中晚期非小细胞肺腺癌患者,国产培美曲塞500mg/m2,静脉滴入,d1;国产奥沙利铂120mg/m2,静脉滴入,d1,21d为1个周期,并口服地塞米松、叶酸和肌肉注射维生素B12以减轻毒副反应。WHO标准评价有效率、疾病进展时间和毒副反应。结果显示,40例患者中,总有效率为32.5%(13/40),疾病控制率为47.5%(19/40),中位疾病进展时间6个月。男性患者与女性患者的有效率分别为33.3%和31.8%,两者之间差异无统计学意义,P=1.0;ⅢB期患者有效率为33.3%,与Ⅳ期患者相比,差异亦无统计学意义,P=0.9。Ⅲ度和Ⅳ度白细胞下降、恶心呕吐、血小板下降及神经毒性的发生率为0。初步研究结果提示,国产培美曲塞联合国产奥沙利铂一线治疗中晚期非小细胞肺腺癌具有较好的疗效和安全性。The objective of this study was to observe the efficacy and safety of domestic pemetrexed and domestic oxaliplatin in the treatment of the patients with patients with mid-advanced non-small cell lung cancer （NSCLC） in first line.A total of 40 patients with pathologically confirmed adenocarcinoma,received pemetrexed 500 mg/m2 and oxaliplatin 120 mg/m2,d1,ivdrip,21 days as one cycle.The patients received oral dexamethasone,oral folic acid and im vitamin B12 supplementation to reduce toxicity.The tumor response and rate toxicity were measured by the WHO criteria.The objective response rate was 32.5%（13/40）.The disease control rates was 47.5%（19/40）.The median progression free survival time was 6 months.The response rates were 33.3% and 31.8% in the male patients and female patients respectively,but no differences was found.The response rate of stage ⅢB patients was 33.3%,and no difference was found as compared with stage Ⅳ patients（P=0.9）.The grade Ⅲ/Ⅳ incidence of leukocyte decrease,nausea and vomiting,decrease of platelet and neurotoxicity was 0.In conclusion,the regiment pemetrexed comhined with oxaliplatin is effective and safe in the treatment of mid-advanced patients with NSCLC in first-line.

关 键 词：癌 非小细胞肺/药物疗法 培美曲塞/治疗应用 奥沙利铂/治疗应用 药物疗法 联合 

分 类 号：R734.2[医药卫生—肿瘤]